These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

993 related items for PubMed ID: 33685242

  • 1. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD, Othee H, Chan KA, Man DC, Belliveau PP, Towle J.
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [Abstract] [Full Text] [Related]

  • 2. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M, Norman K, Sanchorawala V, Siddiqi OK, Hughes D.
    J Cardiovasc Pharmacol; 2021 May 01; 77(5):544-548. PubMed ID: 33657048
    [Abstract] [Full Text] [Related]

  • 3. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
    Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M.
    Nat Rev Cardiol; 2022 Oct 01; 19(10):655-667. PubMed ID: 35322226
    [Abstract] [Full Text] [Related]

  • 4. Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis.
    Plumadore E, Lombardo L, Cabral KP.
    Am J Health Syst Pharm; 2022 Jan 05; 79(2):52-62. PubMed ID: 34491302
    [Abstract] [Full Text] [Related]

  • 5. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
    Maurer MS.
    Am J Cardiol; 2022 Dec 05; 185 Suppl 1():S23-S34. PubMed ID: 36371281
    [Abstract] [Full Text] [Related]

  • 6. Cardiac Amyloidosis Treatment.
    Stern LK, Patel J.
    Methodist Debakey Cardiovasc J; 2022 Dec 05; 18(2):59-72. PubMed ID: 35414852
    [Abstract] [Full Text] [Related]

  • 7. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.
    Vaishnav J, Brown E, Sharma K.
    Prog Cardiovasc Dis; 2024 Dec 05; 82():113-124. PubMed ID: 38246305
    [Abstract] [Full Text] [Related]

  • 8. Developing Therapy for Transthyretin Amyloidosis.
    Campbell CM, Zhang K, Lenihan DJ, Witteles R.
    Am J Med; 2022 Apr 05; 135 Suppl 1():S44-S48. PubMed ID: 35077703
    [Abstract] [Full Text] [Related]

  • 9. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
    Griffin JM, Maurer MS.
    Trends Cardiovasc Med; 2021 Jan 05; 31(1):59-66. PubMed ID: 31889610
    [Abstract] [Full Text] [Related]

  • 10. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J.
    Am J Cardiol; 2021 Jun 01; 148():146-150. PubMed ID: 33667442
    [Abstract] [Full Text] [Related]

  • 11. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y.
    J Neurol Neurosurg Psychiatry; 2015 Sep 01; 86(9):1036-43. PubMed ID: 25604431
    [Abstract] [Full Text] [Related]

  • 12. Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid.
    Hough A, Wearden J, de Almeida K, Kaiser S.
    Curr Cardiol Rep; 2020 Aug 08; 22(10):106. PubMed ID: 32770401
    [Abstract] [Full Text] [Related]

  • 13. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec 08; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 14. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?
    Müller ML, Butler J, Heidecker B.
    Eur J Heart Fail; 2020 Jan 08; 22(1):39-53. PubMed ID: 31912620
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
    Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Piñero D, Rapezzi C, Ueda M, Pinto FJ.
    Glob Heart; 2023 Jan 08; 18(1):59. PubMed ID: 37901600
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.
    Tschöpe C, Elsanhoury A.
    J Clin Med; 2022 Apr 12; 11(8):. PubMed ID: 35456241
    [Abstract] [Full Text] [Related]

  • 19. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials.
    Tomasoni D, Bonfioli GB, Aimo A, Adamo M, Canepa M, Inciardi RM, Lombardi CM, Nardi M, Pagnesi M, Riccardi M, Vergaro G, Vizzardi E, Emdin M, Metra M.
    Front Cardiovasc Med; 2023 Apr 12; 10():1154594. PubMed ID: 37288260
    [Abstract] [Full Text] [Related]

  • 20. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society.
    Grzybowski J, Podolec P, Holcman K, Gawor-Prokopczyk M, Jankowska E, Kostkiewicz M, Dąbrowska-Kugacka A, Lipowska M, Mazurkiewicz Ł, Rajtar-Salwa R, Rubiś P, Straburzyńska-Migaj E, Szczygieł J, Mitkowski P.
    Kardiol Pol; 2023 Apr 12; 81(11):1167-1185. PubMed ID: 37768101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.